Press Releases

22 May 2024

Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo® – and run an active partnering process

16 May 2024

Xbrane Biopharma releases Interim Report for January-March 2024

13 May 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024

10 May 2024

Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US

02 May 2024

Announcement from Xbrane Biopharma’s annual general meeting

21 Apr 2024

Xbrane provides regulatory update on FDA review of its ranibizumab biosimilar candidate

02 Apr 2024

Notice of annual general meeting in Xbrane Biopharma AB

01 Apr 2024

Change of number of shares and votes in Xbrane

27 Mar 2024

XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2023

19 Mar 2024

Xbrane resolves on a directed issue of shares to guarantors in connection with the completed rights issue

14 Mar 2024

Xbrane announces the outcome of the rights issue

08 Mar 2024

Xbrane publish supplement to prospectus

04 Mar 2024

Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company’s rights issue

27 Feb 2024

Trading in unit rights and BTUs in Xbrane’s rights issue will commence on 29 February 2024

27 Feb 2024

Xbrane publishes prospectus in connection with the company’s partially guaranteed rights issue of approximately SEK 343 million

Subscribe to updates regarding Xbrane